ENCePP web header
ENCePP web header
  • Ruthsarian
  • Home
  • Sitemap
  • Q & A
  • Notice Board
    • PhEpi & PhV activities
    • Research Funding
    • Conferences & meetings
    • Recruitment
  • Links
  • Contact Us

Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised OUTCOMES OF THE SPANISH COHORT OF EARLY ACCESS TO PERTUZUMAB AND TRASTUZUMAB EMTANSINE Dr Avendaño-Sola Cristina 30/01/2017
Ongoing Risk of lactic acidosis associated with metformin use in patients with type 2 diabetes and moderate-severe chronic kidney disease: a case-control study Dr Consuelo Pedrós 13/12/2018
Ongoing CHARACTERISATION OF PROTEOMIC PROFILES PREDICTIVE OF HEPATOTOXICITY ASSOCIATED WITH ANTI-TUBERCULOSIS DRUGS: A PILOT STUDY Dr Luisa Ibáñez 29/10/2010
Planned RISK OF AGRANULOCYTOSIS ASSOCIATED WITH THE USE OF DRUGS Professor Joan-Ramon Laporte 03/09/2015
Planned Evaluation of a Standardized Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF Therapy Dr Jordi Gratacós 04/04/2013

  • News
  • About Us
  • ENCePP Documents
  • Training in PhEpi and PV

  • Code of Conduct
  • Standards & Guidances
  • ENCePP Study Seal
  • Public Consultation
  • Glossary of terms

  • Resources Database

  • Partners forum

  • EU PAS Register

  • About EU PAS Register
© 1995-2020 European Medicines Agency | Contact Us | Privacy Policy | Admin Login | Disclaimer

As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period.


combined emea eu logo European Medicines Agency Europa Website
Version: 4.4.1.1